David Jamora, MD
Family Medicine · Hopkinsville, KYNPI 1538420666
Payments from drug & device makers
Across 165 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$671
- Pfizer$251
- Amgen$243
- Shield Therapeutics Inc$218
- Lilly USA, LLC$211
- Novo Nordisk$187
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,839100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $671 |
| Pfizer | 14 | $251 |
| Amgen | 14 | $243 |
| Shield Therapeutics Inc | 5 | $218 |
| Lilly USA, LLC | 14 | $211 |
| Novo Nordisk | 11 | $187 |
| AstraZeneca | 10 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $127 |
| Boehringer Ingelheim | 8 | $123 |
| Bayer | 5 | $104 |
| Dexcom, Inc. | 3 | $69 |
| Amarin Pharma, Inc. | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| GSK | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 3 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Novartis | 2 | $26 |
| Merck | 2 | $23 |
| Johnson & Johnson | 2 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$2,839 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $126,330 |
| JardianceEmpagliflozin | 120 | $124,863 |
| OzempicSemaglutide | 81 | $102,139 |
| TrulicityDulaglutide | 40 | $41,987 |
| JanuviaSitagliptin Phosphate | 41 | $41,727 |
| LinzessLinaclotide | 56 | $37,697 |
| EliquisApixaban | 51 | $34,200 |
| FarxigaDapagliflozin Propanediol | 37 | $28,804 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $21,908 |
| KerendiaFinerenone | 30 | $21,367 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $20,144 |
| VascepaIcosapent Ethyl | 45 | $16,817 |
| RybelsusSemaglutide | 14 | $16,750 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,811 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $11,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $211 | $168,317147 claims |
| Boehringer IngelheimJardiance, Tradjenta | $123 | $134,919138 claims |
| Novo NordiskOzempic, Rybelsus | $187 | $118,88895 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $156 | $47,19973 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $44 | $42,05267 claims |
| MerckJanuvia | $23 | $41,72741 claims |
| AbbVieLinzess | $671 | $37,69756 claims |
| PfizerEliquis | $251 | $34,20051 claims |
| BayerKerendia | $104 | $21,36730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Hopkinsville
- Hunter DavisHopkinsville$15K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.